
News|Articles|July 26, 2004
Antitussive offers convenient twice-daily dosing
The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
4
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
5




























